Mackenzie Financial
LYEL icon

Mackenzie Financial’s Lyell Immunopharma LYEL Stock Holding History

Mackenzie Financial’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-560
Closed -$6.03K – 1768
2025
Q1 		$6.03K Hold
560
– – ﹤0.01% 1666
2024
Q4 		$7.17K Hold
560
– – ﹤0.01% 1690
2024
Q3 		$15.5K Hold
560
– – ﹤0.01% 1571
2024
Q2 		$16.2K Hold
560
– – ﹤0.01% 1521
2024
Q1 		$25K Hold
560
– – ﹤0.01% 1505
2023
Q4 		$21.7K Hold
560
– – ﹤0.01% 1482
2023
Q3 		$16.1K Hold
560
– – ﹤0.01% 1460
2023
Q2 		$34.7K Hold
560
– – ﹤0.01% 1479
2023
Q1 		$26.4K Hold
560
– – ﹤0.01% 1474
2022
Q4 		$38.9K Hold
560
– – ﹤0.01% 1373
2022
Q3 		$82K Sell
560
-30
-5% -$4.06K ﹤0.01% 1322
2022
Q2 		$77K Buy
+590
New +$60.3K ﹤0.01% 1361

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mackenzie Financial's LYEL Position: Q2 2025 in Review

Mackenzie Financial sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 560 shares — an estimated $6.03K sold.

Mackenzie Financial first reported a position in LYEL in Q2 2022 and held it in 12 quarters. The position peaked at $82K in Q3 2022. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Mackenzie Financial reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Mackenzie Financial sold 560 Lyell Immunopharma shares in Q2 2025, an estimated $6.03K.
  • Mackenzie Financial first reported a position in Lyell Immunopharma in Q2 2022 and held it in 12 quarters.
  • Mackenzie Financial's Lyell Immunopharma position peaked at $82K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.